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Aims: Inhibition of ultraviolet-A and -B (UVA+B) skin tumour formation by topical treatment with 
non-steroidal anti-inflammatory drugs (NSAIDs) was investigated in SKH-1 hairless mice. 
Methodology: A UV skin tumour study was designed. Group of mice were irradiated with daily 
doses of UVA+B for approximately 10 min per day, 5 days per week for 10 weeks. After this 10-









. Mice were divided into 4 
groups (n=20 per group). Group 1 was treated with methanol; Group 2 received 2% indomethacin 
in methanol; Group 3 received 2% paracetamol in methanol; Group 4 received 2% flurbiprofen in 
methanol. All groups received their treatment once a day, five days per week for 25 weeks. Mice 
were euthanized after 35 weeks.  
Results: The test NSAIDs in methanol were effective in reducing the incidence and size of the   
skin tumours induced by UVA+B, with a significantly lower average number and/or area of          
skin tumours observed in the NSAID-treated mice compared to the methanol control animals (P < 
.05). 











Conclusion: The results support the hypothesis that topically applied indomethacin, paracetamol, 
and flurbiprofen can provide protection against skin cancer, even when applied well after the skin 
has been exposed to the damaging effects of UV-light.  
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Skin cancer is the most common type of cancer 
for males and females in the white population [1]. 
Among the various malignant skin cancer types, 
non-melanoma skin cancer (NMSC), including 
basal cell carcinoma (BCC) and squamous cell 
carcinoma (SCC) is most common, and is a 
source of significant morbidity. Basal cell 
carcinoma represents about 80% of all reported 
skin cancers, while squamous cell carcinoma is 
about 16%, and melanomas represent about 4% 
[1,2]. Most NMSC occurs in people over 40 years 
of age, and incidence rates in Australia are 
believed to be the highest in the world [3]. A 2-
fold increase in NMSC incidence has also been 
seen in the United States from 1994 to 2006 [4]. 
People with light complexions, fair or red hair and 
who tend to burn easily on exposure to the sun 
(Fitzpatrick skin grades 1 and 2) are more prone 
to develop NMSC than those with dark-skin, and 
males appear to be at higher risk [3].  
 
Once treated for a NMSC, the risk of developing 
a new NMSC is highest in the subsequent year 
[3]. From an early review of 7 studies, it has been 
established that the 3-year cumulative risk for a 
subsequent NMSC is on average 44% [5]. There 
is also a strong association between the risk of 
developing a subsequent skin cancer and the 
number of prior skin tumours - that is, the more 
prior skin cancers, the higher the risk.  In one 
study, the risk was increased from 38% for 
patients with fewer than 3 previous NMSC to 
93% for patients with 3 to 9 previous NMSC [6]. 
Healthcare costs associated with the treatment of 
skin cancers are over 500 million annually in the 
United States alone, and it has been estimated 
that at current rates, 1 in 5 Americans will 
develop a skin cancer of some sort during their 
lifetime [7,8]. Clearly skin cancer is a major 
worldwide health problem and is a very costly 
disease to treat and manage. 
 
There is a causal relationship between excessive 
exposure to solar ultraviolet (UV) radiation and 
incidence of skin cancers [3,9]. UV light has been 
reported as being the main aetiology of NMSC 
due to DNA damages, such as the creation of 
clyclobutane dimers and nucleotide mutations 
[9]. Moreover, p53-gene mutations resulted from 
UV light could inactivate the p53-gene’s ability to 
inhibit tumor promotions in mutated cells [10]. 
Preventive methods for NMSC include standard 
sun protection behaviours, such as applying 
sunscreen creams with high SPF (sun protection 
factor), avoiding UV peak hours or periods, and 
minimising exposure to UV light with protective 
clothing. As total avoidance of sun exposure 
would seem unrealistic, other interventions to 
prevent NMSC are needed. This is greatly 
beneficial for patients with precursor lesions such 
as Actinic keratosis, as chemoprevention may 
inhibit the development of the condition into 
malignancy [11]. 
 
Earlier studies have shown that non-steroid anti-
inflammatory drugs (NSAIDs) have a potential 
role in cancer prevention, including NMSC [12-
15] by inhibition of cyclooxygenase enzymes 
COX-1 and COX-2, which are involved in 
carcinogenesis [16]. Chemically, NSAIDs are 
divided into a number of subclasses. They 
include the salicylic acid derivatives - e.g. aspirin, 
the indole and indene acetic acids - e.g. 
indomethacin, the heteroaryl acetic acids - e.g. 
diclofenac, and the arylpropionic acid derivatives 
- e.g. flurbiprofen [17]. Paracetamol is considered 
as an atypical NSAID as it is a week inhibitor of 
COXs. Several studies have reported that COX-2 
is up-regulated in many forms of cancer, 
including human colorectal adenocarcinoma, 
breast, cervical, prostate, lung and skin     
tumours [18,19], and have indicated a                         
relationship between the NSAID antiproliferative 
effect and COX inhibition [20-23]. Several                
lines of evidence also suggested that 
antiproliferative effects of NSAIDs are mediated 
via mechanisms that are at least partly 
independent of COX inhibition [22,24-27]. The 
role of COX inhibition in NSAID     
antiproliferative effect is presently unclear. 
Recently, a study by Sørensen also reported that 
the use of NSAID, including non-selective 
NSAIDs, overall reduced the risk of certain types 
of skin cancer [28]. 
 
To test the relative effectiveness of NSAIDs as 











hairless mice was designed. It was found that 
topical NSAIDs from 3 subclasses; indomethacin, 
flurbiprofen, and paracetamol can provide 
protection against skin cancer even when applied 
well after the skin has been exposed to the 
damaging effects of UV-light. The results of the 
tumor study and the effects of the three test 
NSAIDs, including indomethacin, flurbiprofen, 
and paracetamol that has a weak COX inhibition 
action are presented in this paper. 
 
2. MATERIALS AND METHODS  
 
2.1 Chemicals and Reagents 
 
Indomethacin, paracetamol, and flurbiprofen 
were obtained from the Sigma Chemical 
Company (Castle Hill, NSW, Australia). Methanol 
and other chemicals were purchased from Biolab 
(Clayton, VIC, Australia). All other chemicals 





All animals received human care according to the 
“Australian code for the care and use of animals 
for scientific purposes” (National Health and 
Medical Research Council, NHMRC, AE-16 7
th
 
Edition 2004). The Animal Ethics Committee at 
The University of South Australia approved the 
study protocols for all animal experiments.  
 
Female SKH-1 mice were obtained from the 
Animal Resource Centre (Perth, Western 
Australia) at four weeks of age. Animals were 
randomly allocated to one of four treatment 
groups and allowed free access to a standard 
diet formulated according to the American 
Institute of Nutrition (AIN-89 diet, Glen Forrest 
Feeds, Perth, WA. Australia). The animals were 
acclimatized and caged together in groups of 10 
mice. The mice were maintained under standard 
conditions of a 12 h dark/12 h light cycle, at the 
temperature of 24±2ºC, and relative humidity of 
50 ± 10%.  
 
2.3 UV Source 
 
A purpose-built apparatus was used for UV 
irradiation. The UV emission was produced by 6 
UV-A lamps (model 40BL, Sylvania) 
symmetrically housed around a single UV-B lamp 
(model FL40SE, Philips). The spectrum was 
measured with a spectroradiometer (model IL 
1700, International Light, Newburyport, MA). The 
integrated UV-A irradiance (280-320 nm) was 2.4 
x 10-4 W/cm2 and the UV-B irradiance (320-400 






2.4 Irradiation of Mice 
 
After one week of acclimatization, animals in all 
groups were exposed to UVA+B approximating 
solar UV emission as described above. 
Irradiation was commenced at 5 min/day and 
increased to a maximum of 10 min/day. Animals 
showing undue reddening of the skin (i.e., >2 
minimal erythematous dose) were not irradiated 
further until the erythema had disappeared. 
Differences between cumulative doses did not 
exceed 1% of the total UV exposure. No mice 
exhibited any evidence of blister formation or 
skin peeling. Mice were irradiated once daily, 5 
days per week for 10 weeks. After this 10-week 
irradiation, there was no further UV exposure.   
 
2.5 Tumor Study 
 
Mice in all groups (n = 20 per group) were 
irradiated daily for 10 weeks with UVA+B as 
described above. After exposure to UV for 10 
weeks, mice were painted dorsally with (Group 1) 
70% methanol, (Group 2) 2% indomethacin in 
70% methanol, (Group 3) 2% paracetamol in 
70% methanol, (Group 4) 2% flurbiprofen in 70% 
methanol. The selection of the dose of 2% of 
topical NSAID was based on preliminary 
experiments testing a range of concentrations of 
NSAIDs (from 0.5% up to 3%) on a small number 
of animals.  
 
All groups received their treatment once a day, 
five days per week for 25 weeks. Animals were 
monitored daily for their appearance, and as 
papillomas or tumours appeared, they were 
counted and measured regularly. After 35 weeks, 
the experiment was ended, and all the mice were 
euthanized with a lethal dose of pentobarbital 
sodium (Nembutal).  
 
2.6 Statistical Analysis 
 
Statistical analysis was performed using 
Microsoft Excel software. Tumour multiplicity and 
total tumor area were compared between the 
control group and the NSAID treated groups. 
Tumor multiplicity, expressed as the mean 
number of tumours, the mean number of tumours 
plus papillomas per animal, and the total  
affected area were analysed by Student's t test. 
A P value < .05 was considered to be significant. 











transformed using the square root of the area, 
prior to performing the Student's t test. Data     
are presented as mean ± SD of total 
animals/group.  
 
3. RESULTS  
 
3.1 Mice Survival 
 
The majority of the mice survived the full 35-
week study (see Table 1). The deaths were 
higher in two of drug treatment groups than the 
placebo. A number of mice in the indomethacin 
group did not survive the entire experimental 
period and died due to noticeable NSAID’s 
toxicity, such as GI disturbance, bleeding which 
may be possibly resulted from systemic 
absorption of indomethacin. Two mice in the 
flurbiprofen group died in week 30 and 31 of the 
study. No drug toxicity or other causes of death 
were observed for other groups. 
 
3.2 Evaluation of Chemopreventive 
Effects 
 
The incidence of tumours, the mean number of 
tumours and mean number of tumours plus 
papillomas, and the total areas found in the 
various groups at the end of the 35-week study 
are summarized in Table 2. No tumours or 
papillomas were present in mice during the 10 
weeks of UV exposure. Data are presented as 
tumours, and tumours plus papillomas as the 
natural progression of UVA+B-induced skin 
cancer is from the initiated cell to a benign 
papilloma to cancer (defined as an invasive 
lesion) and in some cases the distinction could 
not be made unequivocally. 
  
The incidence of UVA+B-induced skin tumours 
was reduced in the groups treated with 
paracetamol and indomethacin, to about two-
thirds and four-fifths that of the methanol only 
group, respectively. The mean number of 
tumours was reduced in the NSAID treated 
groups and was statistically significant for 
paracetamol (P < .05), but not for indomethacin 
and flubiprofen possibly due to the large 
standard errors. The mean number of tumours 
plus papillomas was also lower and was 
statistically significant for indomethacin and 
paracetamol (P < .05), not for flurbiprofen. 
 
The mean area of the tumours and the mean 
area of tumours plus papillomas were also 
calculated as an index of tumour burden on the 
mice. Both the mean area of tumours (see Table 
2) and the mean area of tumours plus papillomas 
were significantly reduced in mice treated with 
indomethacin and flurbiprofen than that in 
methanol control animals (P < .05); but were not 
statistically significant for paracetamol. The mean 
area of tumours plus papillomas is presented in 
Fig. 1. 
 
Table 1. Number of surviving mice in each group during 25 weeks of topical treatment with 2% 




Week number 24 25 26 27 28 29 30 31 32 33 34 35 
Placebo 20 20 20 20 20 20 20 20 20 20 19 19 
Paracetamol 20 20 20 20 20 20 20 20 20 20 20 20 
Flurbiprofen 20 20 20 20 20 20 19 18 18 18 18 18 
Indomethacin 20 20 19 19 18 17 15 15 15 15 15 15 
a
 Each group, originally contained 20 mice, which were subjected to 10 week UV-irradiation, then 25 week topical 
drug treatment 
 
Table 2. Tumor multiplicity and burden in mice receiving topical treatment with 2% 




 Survival Percentage of surviving 
mice with tumours 
Tumoursb Tumours & 
Papillomas
b
    Number Area (mm2) 
Methanol   19 68% 1.53 ± 0.96 14.68 ± 11.24 1.76 ± 0.83 
Indomethacin 15 53% 0.66 ± 0.51 1.1 ± 0.48
*
 1.16 ± 0.40
*
 
Paracetamol 20 45% 1.00 ± 0.57* 3.41 ± 4.00 1.28 ± 0.48* 
Flurbiprofen 18 61% 0.88 ± 0.60 5.27 ± 4.19
*
 1.55 ± 0.78 
a
Each group originally contained 20 mice: survival values are the number of mice alive after 35 weeks. 
b
 Mean ± S.D. 
*
Mean number of tumours, mean area of tumours, and mean number of tumours + papillomas 














Fig. 1. The mean total area of tumours and papillomas per mouse in the NSAID treated groups 
compared to the placebo at the end of the study 




In this study, inhibition of UVA+B-induced skin 
tumour formation by 3 test NSAIDs from different 
subclasses; indomethacin, flurbiprofen, and 
paracetamol adds further support to the 
hypothesis that NSAIDs can provide protection 
against skin cancer, even when applied well after 
the skin has been exposed to the damaging 
effects of UV-light. This finding is particularly 
significant given the latency period of skin cancer 
in humans. 
 
The chemopreventive treatments with systemic 
NSAIDs, including aspirin, ibuprofen, 
indomethacin and paracetamol have previously 
been shown to reduce the risk of developing 
NMSC [12-14,29]. Previous human population-
based case-control studies demonstrated a 
reduced risk of having NMSC in ibuprofen 
[12,13], indomethacin [12], paracetamol [13] and 
aspirin users [13]. Lower risk of NMSC with 
paracetamol use has also been found in previous 
human prospective study, with a reduced risk 
associated with a higher frequency of use (P = 
.04) [29]. An RCT in 1402 AK (actinic keratosis) 
patients resulted in a reduction in the risk of 
developing NMSC for aspirin treatment [14]. It 
has earlier been shown that orally administered 
NSAID indomethacin [30] and celecoxib could 
inhibit development of UVB induced skin tumours 
in mice [30-33] and in human RCT [34]. 
Unfortunately, because of the toxicity of 
indomethacin due to systematic absorption, it 
was not possible to study its effects at higher 
concentrations. Regarding the use of topical 
NSAIDs, only one earlier study has shown a 
delayed onset and reduced development of skin 
tumours in mice using celecoxib combined with 
zileuton, a 5-lipoxygenase inhibitor [35].  In the 
present study, topical indomethacin was shown 
to have the greatest protective effects compared 
to paracetamol and flurbiprofen. However, it was 
also associated with a lower survival of mice, 
which was consistent with that reported in the 
literature. Overall, 3 test compounds, including 
week COX inhibitor paracetamol,                            
were effective in reducing the mean number 
and/or area of skin tumours in hairless mice that 
had been exposed to UVA+B light only during 
earlier stages of their life (before drug treatment 
was commenced). The results of this study 
further support the potential use of NSAIDs as 




The results support the hypothesis that topically 
applied indomethacin, paracetamol, and 
flurbiprofen can provide protection against skin 
cancer, even when applied well after the skin has 











light. As topical administration of drugs would 
lead to less side effects compared with systemic 
administration, the idea of topical NSAID to 
prevent UV-induced NMSC with minimal 
cardiovascular complications and gastrointestinal 
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